Aprea Therapeutics, Inc. (APRE) has successfully closed a $30 million private placement financing, aimed at bolstering its research and development efforts. The oversubscribed round, led by Soleus Capital, will support ongoing clinical trials for its lead candidates, APR-1051 and ATRN-119, both targeting advanced solid tumors. The company’s recent updates on APR-1051’s positive clinical activity have garnered attention, with Wedbush analyst Robert Driscoll maintaining an Outperform rating and a price target of $7.

This financing comes at a critical time as Aprea reported $14.6 million in cash and equivalents as of December 31, 2025, projecting a cash runway into Q1 2027. Despite the positive developments, APRE shares have seen volatility, closing at $0.70, down 7.75%, and further declining to $0.67 in after-hours trading.

Investors should monitor Aprea’s upcoming trial updates in Q2 2026, as they could significantly influence stock performance and investor sentiment in the biopharmaceutical sector.

Source: nasdaq.com